PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1100
-0.0500 (-1.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.1600
Open3.1700
Bid0.00 x 900
Ask0.00 x 3200
Day's Range3.0900 - 3.2100
52 Week Range2.2500 - 3.2200
Volume1,033,282
Avg. Volume1,660,253
Market Cap453.985M
Beta (3Y Monthly)0.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-02
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    Biotech and Cannabis Stocks to Watch

    With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: ...

  • PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

    INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare ...

  • ACCESSWIRE2 months ago

    3 Health Care Stocks Rallying After US Midterms

    / Healthcare stocks are rallying after Tuesday's US midterm elections. According to Modern Healthcare* the healthcare industry will continue to drive the nation's employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to Bureau of Labor Statistics data. Modern Healthcare cites that ''the healthcare industry has long fueled the country's economy.

  • PDL BioPharma Reports Third Quarter 2018 Financial Results
    PR Newswire2 months ago

    PDL BioPharma Reports Third Quarter 2018 Financial Results

    Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three ...

  • PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
    PR Newswire3 months ago

    PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018

    INCLINE VILLAGE, Nev., Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close.  PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com. To access the live and subsequently archived webcast of the conference call, go to the Company's website and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PDL BioPharma Names Edward Imbrogno Vice President of Finance
    PR Newswire3 months ago

    PDL BioPharma Names Edward Imbrogno Vice President of Finance

    INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. ...

  • PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
    PR Newswire4 months ago

    PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • PDL BioPharma Announces New $100 Million Stock Repurchase Program
    PR Newswire4 months ago

    PDL BioPharma Announces New $100 Million Stock Repurchase Program

    INCLINE VILLAGE, Nev., Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission. "We believe this program is an appropriate means to create shareholder value given the current discrepancy between our share price and our book value," said John McLaughlin, Chief Executive Officer of PDL. The timing of purchases and the number of shares repurchased under the new program by PDL will depend on a variety of factors including price, trading volume, corporate and regulatory requirements and market conditions.  Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when PDL might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.

  • PR Newswire4 months ago

    SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma

    Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value Believes the PDL Board Must Pursue Alternative Capital Allocation Strategies, Including ...

  • PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire5 months ago

    PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • PDL BioPharma Reports Second Quarter 2018 Financial Results
    PR Newswire5 months ago

    PDL BioPharma Reports Second Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, ...

  • ACCESSWIRE5 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
    PR Newswire5 months ago

    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

    INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") ...

  • PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018
    PR Newswire6 months ago

    PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018

    INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial ...

  • ACCESSWIRE6 months ago

    Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on PIRS sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Pacific Biosciences of California Inc. (NASDAQ: PACB), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).

  • Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors
    PR Newswire7 months ago

    Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth ...

  • Shlomo Yanai Elected to PDL BioPharma's Board of Directors
    PR Newswire7 months ago

    Shlomo Yanai Elected to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 11, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June ...

  • PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
    PR Newswire8 months ago

    PDL BioPharma Names Dr. Jill Jene Vice President, Business Development

    INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet. "Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products.

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire8 months ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , May 15, 2018 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will present at the following two upcoming investor conferences: UBS Global ...

  • PDL BioPharma Announces First Quarter 2018 Financial Results
    PR Newswire8 months ago

    PDL BioPharma Announces First Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , May 9, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2018 including: Total ...